Table 3.
Frequency of HLA-C and inhibitory KIR genotypes in HCV patients with Spontaneous Clearance and Chronic Viremia
| SC | CV | |||
|---|---|---|---|---|
| N = 3* | N = 121 | |||
| n (%) | n (%) | OR (CI) | p value | |
| HLA-C group genotypes | ||||
| C1/C1 (−) | 22 (56.5) | 85 (70.2) | 1 | - |
| C1/C1 | 17 (43.5) | 35 (28.9) | 1.88 (0.82–4.20) | 0.11 |
| Inhibitory genotypes | ||||
| 2DL3/2DL3 (−) | 18 (46.2) | 74 (61.2) | 1 | - |
| 2DL3/2DL3 | 21 (53.8) | 47 (38.8) | 1.84 (0.89–3 79) | 0.1 |
| HLA-C1+inhibitory genotypes | ||||
| C1/C1 (−) + 2DL3/2DL3(−) | 13 (33.3) | 54 (45.0) | 1 | - |
| C1/C1 (−) + 2DL3/2DL3 | 9 (23.1) | 31 (25.8) | 1.20 (0.40–3.46) | 0.8 |
| C1/C1 + 2DL3/2DL3 (−) | 6 (15.4) | 20 (16.7) | 1.25 (0.34–4.12) | 0.78 |
| C1/C1 +2DL3/2DL3 | 11 (28.2) | 15 (12.5) | 3.05 (1.00–9.08) | 0.03 |
C1/C1: 2 copies of C1 alleles; C1/C1 (− ): C1/C2 + C2/C2; KIR inhibitory genotypes: 2DL3/2DL3: (2DL3 (+), 2DL2 (−), 2DS2 (−); 2DL3/2DL3 (−): 2DL2 (+), 2DL3 (−) 2DS2 (+); SC: spontaneous clearance, CV: chronic viremia; OR: Odds Ratio; CI: 95% Confidence Interval.